PURMX Therapeutics Receives Orphan Drug Designation for miR-3140-3p from the U.S. FDA
- tomokokikuchi4
- 29 minutes ago
- 1 min read
PURMX Therapeutics Inc. (hereinafter “PURMX”), headquartered in Hiroshima, Japan and led by President and CEO Hidetoshi Tahara, announced that on May 6, 2025, it received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for miR-3140-3p, a naturally occurring microRNA currently under clinical development by the company.